Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
October 5, 2009
- Mirtazapine Shows Fast, Long-Lasting Effects: Prof. Kinoshita
October 5, 2009
- Team Nagatsuma Sets Out
October 5, 2009
- TOPICS／Dr Karasawa Intends to Lead JMA for Another Term of Office
October 5, 2009
- Caduet to Target Patients Untreated for Hypertension or Hypercholesterolemia
September 28, 2009
- 9th Kitasato Harvard Symposium
September 28, 2009
- Deep Valley of Death Ahead of Japanese Bioventures: Mr Yoshida
September 28, 2009
- R&D CARE NEWS IN BRIEF
September 28, 2009
- Proposed Acquisition of Sepracor by DSP Solves Both Parties Problems
September 28, 2009
- JMA Calls For Periodical Vaccination Programs for Hib, HPV
September 28, 2009
- 6 Mediceo Paltac Subsidiaries to Merge on Oct. 1
September 28, 2009
- Koroshos WG Presents Recommendation on Use of Antipsychotics
September 28, 2009
- Drug Wholesalers Should Compete on the Strength of Their General Capability: Mr Kinoshita
September 28, 2009
- Promotional Activities for Pariet Have Greatest Impact on Prescription: Survey
September 28, 2009
- Cravit Remains No. 1 on Both HP and GP Markets: Rep Track Survey
September 28, 2009
- Support from Drug Makers Influence Doctors Prescription
September 28, 2009
- BUSINESS NEWS IN BRIEF
September 28, 2009
- SEMINAR
September 28, 2009
- Fundamentally Review Budget Formation Process: Mr Hatoyama
September 28, 2009
- 24-Year-Old Woman without Underlying Disease Dies due to New-Type Flu
September 28, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…